Drugs · acquisition-cost intelligence
Adderall XR
Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate· ingredient dextroamphetamineCentrally acting sympathomimetics· AMPHETAMINE ASPARTATE MONOHYDRATE 1.25 mg/1; AMPHETAMINE SULFATE 1.25 mg/1; AMPHETAMINE ASPARTATE MONOHYDRATE 2.5 mg/1; AMPHETAMINE SULFATE 2.5 mg/1; AMPHETAMINE ASPARTATE MONOHYDRATE 3.75 mg/1; AMPHETAMINE SULFATE 3.75 mg/1; AMPHETAMINE ASPARTATE MONOHYDRATE 5 mg/1; AMPHETAMINE SULFATE 5 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.54992
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other dextroamphetamine products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Adderall | $0.25990 | −$0.29000 |
| Zenzedi | $0.42657 | −$0.12330 |
| PROCENTRA | $1.11 | +$0.56190 |
| DEXEDRINE SPANSULE | $1.34 | +$0.78750 |
| Mixed Salts of a Single-Entity Amphetamine Product | $8.51 | +$7.96 |
| XELSTRYM | $16.26 | +$15.71 |
Medicare Part D coverage · CY2026
On 320 plan formularies · typical tier 4
Prior auth 20% · Step therapy 0% · Quantity limit 81% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.